A Health Canada safety review confirmed a potential risk for gastric perforation, esophageal perforation, acute pancreatitis and spontaneous balloon overinflation associated with the use of intragastric balloons in weight loss therapy.
Products affected
|
Medical Device Name |
Manufacturer |
Device Licence Numbers |
|
(*device no longer licensed in Canada as of February 2019)
|
|
Orbera System Intragastric Balloon |
Apollo Endosurgery Inc. |
72168 |
|
Spatz3 Adjustable Balloon System Insertion Kit |
Spatz Fgia (Israel) Ltd. |
93172 |
|
*Endball – Systeme de Ballon Intra-gastrique |
Endalis |
90070 |
|
*Reshape Medical Intragastric Balloon |
Reshape Medical |
84060 |
Background information
Intragastric balloons are fluid or air-filled medical devices placed in the stomach to act as a space-occupying device. They are temporary devices (6 or 12 months maximum use, according to the licence) used for weight loss along with other measures (diet, exercise) in obese patients. They are inserted and removed endoscopically. At the time of the safety review, 4 models of intragastric balloons were licensed for sale in Canada. All were fluid-filled devices, with the first model being licensed in 2006. At present, 2 models of intragastric balloon remain licensed in Canada.
Though there is some evidence to show the potential effectiveness of these devices in contributing to patient weight loss, Health Canada is aware of various complications associated with these devices including gastric perforation, esophageal perforation, acute pancreatitis, and spontaneous balloon overinflation.
At the time of the review, there were 4 adverse events that had been reported to Health Canada that were associated with the use of intragastric balloons. Two of these 4 reports were international and 2 reports were Canadian. One of the international reports involved gastric wall injury and bleeding at the time of device insertion and inflation. The other international report involved a perforating gastric ulcer that occurred 10-days after intragastric balloon implantation. In both international cases patients recovered after the intragastric balloons were removed. The 2 Canadian reports involved deaths but there was not enough information to confirm the exact cause of the deaths.
A review of the medical literature revealed 26 cases of gastric perforation associated with intragastric balloons, including 6 deaths. Most cases were reported to have occurred between 9 days and 5 months after placement (overall range from several hours to 22 months after placement) and predominant symptoms at presentation were severe abdominal pain and nausea. Almost all cases required urgent surgical intervention (laparoscopy or laparotomy). The estimated risk of a stomach perforation spanning the full thickness of the stomach in IB users is believed to be 0.1 to 0.2%, but the frequency of partial thickness injuries (ulcer) to the stomach wall is likely higher.
Two detailed cases of esophageal perforation associated with intragastric balloon therapy were found in the literature. One was associated with a difficult balloon insertion and one with a difficult removal; both patients recovered. Other cases of esophageal perforation related to intragastric balloons, including one fatality, were found in a review of international adverse event databases. Esophageal perforation is a known, but very rare risk associated with both diagnostic and therapeutic endoscopy of the upper gastrointestinal tract.
Seventeen confirmed cases of acute pancreatitis associated with intragastric balloons were found in the literature. Severe abdominal pain, nausea and vomiting were the most commonly reported symptoms. Cases were reported to have occurred between one day and 11 months after balloon insertion. Most patients were treated by endoscopic balloon removal while two patients required surgery. All patients recovered. Acute pancreatitis is believed to occur in these cases through mechanical pressure exerted by the balloon on the pancreas through the gastric wall.
Only one detailed case of spontaneous overinflation of an intragastric balloon was found in the literature. The event was confirmed by radiographic imaging. The balloon was removed endoscopically and the patient recovered. Mention of other balloon overinflation cases was found in the literature, but no other cases were described in detail. International adverse event databases were also found to contain multiple reports of this complication leading to early removal of the intragastric balloon.